Continued investment in research and development

「Research and development expenses amounted to ¥172,174 million, up 5.7% year on year. Development expenses increased as Phase III trials progressed for repinatrabit, which is being developed as a treatment for phenylketonuria, and quabodepistat, which is being developed as an antituberculosis drug, among others.」

「Research and development expenses amounted to ¥172,174 million, up 5.7% year on year. Development expenses increased as Phase III trials progressed for repinatrabit, which is being developed as a treatment for phenylketonuria, and quabodepistat, which is being developed as an antituberculosis drug, among others.」

「Research and development expenses amounted to ¥82,101 million, up 4.7% year on year. Among development products, expenses increased for the “Next 8” products, including the novel antipsychotic ulotaront, ASTX030, which is being developed as a treatment for hematological cancers, and repinatrabit, which is being developed as a treatment for phenylketonuria.」

「Continued investment of approximately ¥300 billion in R&D, underpinned by stable financial conditions at historically high levels」

「R&D expenses amounted to ¥162,903 million, up 13.2% year on year. Among development products, development costs increased for the Next 8 products, including the novel antipsychotic ulotaront, zipalertinib, which is being developed for non-small cell lung cancer, and repinatrabit from Junana, acquired in the previous consolidated fiscal year.」

「R&D expenses amounted to ¥314,233 million, up 2.1% year on year.」

「R&D expenses amounted to ¥143,949 million, up 1.3% year on year, but declined from the same period of the previous year excluding the impact of foreign exchange rates. Among development products, development costs increased for sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and ulotaront/SEP-363856, a novel antipsychotic licensed from Sumitomo Pharma Co.,Ltd., while development costs for brexpiprazole declined following the completion of several Phase 3 trials.」

「R&D expenses amounted to ¥72,387 million, up 6.5% year on year, but were broadly in line with the same period of the previous year excluding the impact of foreign exchange rates. Among development products, development costs increased for sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and zimberelimab/AB122 and domvanalimab/AB154, licensed from Arcus, reflecting their steady progress, while development costs for brexpiprazole declined following the completion of several Phase 3 trials.」

「R&D expenses for the consolidated fiscal year were ¥307,804 million.」

「R&D expenses amounted to ¥215,637 million, up 11.3% year on year. The main factors behind the increase were development costs under the license agreement with Sumitomo Pharma Co.,Ltd. covering the co-development and commercialization of an antipsychotic with a novel mechanism of action, the steady progress of zipalertinib/TAS6417, which is being developed for non-small cell lung cancer, and sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and the impact of foreign exchange rates.」

「R&D expenses amounted to ¥142,103 million, up 13.5% year on year. The main factors behind the increase were development costs under the license agreement with Sumitomo Pharma Co.,Ltd. covering the co-development and commercialization of an antipsychotic with a novel mechanism of action as part of efforts to pursue new treatment possibilities, the steady progress of zipalertinib/TAS6417, which is being developed for non-small cell lung cancer, and sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and the impact of foreign exchange rates.」

「R&D expenses amounted to ¥67,968 million, up 14.5% year on year. The main factors behind the increase were the steady progress of centanafadine, which is being developed for attention-deficit/hyperactivity disorder and other indications, and zipalertinib/TAS6417, which is being developed for non-small cell lung cancer, higher development costs under the license agreement with Sumitomo Pharma Co.,Ltd. and Sunovion covering the co-development and commercialization of an antipsychotic with a novel mechanism of action as part of efforts to pursue new treatment possibilities, and the impact of foreign exchange rates.」

「R&D expenses amounted to ¥275,230 million, up 18.5% year on year. The main factors behind the increase were higher development costs for centanafadine, which is being developed for attention-deficit/hyperactivity disorder and other indications, and sibeprenlimab/VIS649, which is being developed for IgA nephropathy, reflecting their steady progress, higher development costs under the license agreement with Sumitomo Pharma Co.,Ltd. and Sunovion covering the co-development and commercialization of an antipsychotic with a novel mechanism of action as part of efforts to pursue new treatment possibilities, and the impact of foreign exchange rates.」

「R&D expenses amounted to ¥193,765 million, up 19.2% year on year. The main factors behind the increase were higher development costs for centanafadine, which is being developed for attention-deficit/hyperactivity disorder and other indications, and sibeprenlimab/VIS649, which is being developed for IgA nephropathy, reflecting their steady progress, higher development costs under the license agreement with Sumitomo Pharma Co.,Ltd. and Sunovion covering the co-development and commercialization of an antipsychotic with a novel mechanism of action as part of efforts to pursue new treatment possibilities, and the impact of foreign exchange rates.」

「R&D expenses amounted to ¥125,208 million, up 21.7% year on year, due to higher development costs under the license agreement with Sumitomo Pharma Co.,Ltd. and Sunovion covering the co-development and commercialization of an antipsychotic with a novel mechanism of action, higher development costs for centanafadine, which is being developed for attention-deficit/hyperactivity disorder and binge-eating disorder in children, higher development costs for sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and the impact of foreign exchange rates,」

「R&D expenses amounted to ¥59,347 million, up 22.1% year on year, due to higher development costs under the license agreement with Sumitomo Pharma Co.,Ltd. and Sunovion covering the co-development and commercialization of an antipsychotic with a novel mechanism of action, higher development costs for centanafadine, for which new clinical trials were initiated in children with attention-deficit/hyperactivity disorder and binge-eating disorder, higher development costs for sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and the impact of foreign exchange rates,」

「R&D expenses for the consolidated fiscal year were ¥232,299 million.」

「R&D expenses amounted to ¥162,521 million, up 2.8% year on year,」

「R&D expenses amounted to ¥102,919 million, down 5.8% year on year, due to lower development costs for vadadustat, centanafadine, fremanezumab and other products.」

「R&D expenses amounted to ¥48,603 million, down 10.5% year on year, due to lower development costs for vadadustat, centanafadine, fremanezumab and other products,」

「R&D expenses for the consolidated fiscal year were ¥216,841 million.」

「R&D expenses for the 9-month period ended the third quarter were ¥158,059 million.」

「R&D expenses for the 6-month period ended the second quarter were ¥109,210 million.」

「R&D expenses for the 3-month period ended the first quarter were ¥54,322 million.」

「R&D expenses for the fiscal year were ¥215,789 million.」

「R&D expenses rose to ¥153,939 million, up 12.9% year on year, due to higher development costs for AVP-786, an ultrasound renal denervation treatment device, centanafadine, Rexulti, TAS-120 and products under development by ビステラ社,」

「R&D expenses were ¥51,042 million, up 20.9% year on year, while business profit was ¥33,364 million, down 3.6%.」

「R&D expenses for the fiscal year were ¥216,140 million.」

「R&D expenses for the 9-month period ended the third quarter were ¥158,806 million.」

「R&D expenses for the 6-month period ended the second quarter were ¥96,079 million.」

「R&D expenses for the 3-month period ended the first quarter were ¥42,613 million.」

「R&D expenses for the fiscal year were ¥175,558 million.」

「R&D expenses for the 9-month period ended the third quarter were ¥121,930 million.」

「R&D expenses for the 6-month period ended the second quarter were ¥80,765 million.」

「R&D expenses for the 3-month period ended the first quarter were ¥36,658 million.」

「R&D expenses for the fiscal year were ¥168,818 million.」

「R&D expenses for the 9-month period ended the third quarter were ¥105,151 million.」

「R&D expenses for the 6-month period ended the second quarter were ¥71,798 million.」